Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-α gene therapy for pancreatic cancer

Cancer Science

Volumn 105, Issue 2, 2014, Pages 159-167

  Aida, Kouichirou ^a,b   Miyakawa, Reina ^a   Suzuki, Koji ^a   Narumi, Kenta ^a   Udagawa, Takeshi ^a,b   Yamamoto, Yuki ^a   Chikaraishi, Tatsuya ^b   Yoshida, Teruhiko ^a   Aoki, Kazunori ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti glucocorticoid induced TNF receptor antibody; Interferon gene therapy; Pancreatic cancer

Indexed keywords

ADENOVIRUS VECTOR; ALPHA INTERFERON; ANTI GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR MONOCLONAL ANTIBODY; CHEMOKINE RECEPTOR CCR5; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; MONOCLONAL ANTIBODY; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTITUMOR IMMUNITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SIZE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUNCTION; CELL INFILTRATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG POTENTIATION; FEMALE; LOW DRUG DOSE; MOUSE; NEOPLASM; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SPLEEN CELL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; VIRAL GENE DELIVERY SYSTEM;

ANTI-GLUCOCORTICOID INDUCED TNF RECEPTOR ANTIBODY; INTERFERON-Α GENE THERAPY; PANCREATIC CANCER;

ANIMALS; ANTIBODIES, MONOCLONAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; IMMUNE TOLERANCE; IMMUNOTHERAPY; INJECTIONS, INTRALESIONAL; INTERFERON-ALPHA; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PANCREATIC NEOPLASMS; RECEPTORS, TUMOR NECROSIS FACTOR; T-LYMPHOCYTES, REGULATORY; TUMOR MICROENVIRONMENT;

EID: 84893761324     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12332     Document Type: Article

References (30)

1. Hackert T, Buchler MW. Pancreatic cancer: advances in treatment, results and limitations. Dig Dis 2013; 31: 51-6.
2. Paulson AS, Tran Cao HS, Tempero MA, Lowy AM. Therapeutic advances in pancreatic cancer. Gastroenterology 2013; 144: 1316-26.
3. Werner J, Combs SE, Springfeld C, Hartwig W, Hackert T, Buchler MW. Advanced-stage pancreatic cancer: therapy options. Nat Rev Clin Oncol 2013; 10: 323-33.
4. Okusaka T, Matsumura Y, Aoki K. New approaches for pancreatic cancer in Japan. Cancer Chemother Pharmacol 2004; 54 (Suppl. 1): S78-82.
5. Yoshida T, Ohnami S, Aoki K. Development of gene therapy to target pancreatic cancer. Cancer Sci 2004; 95: 283-9.
6. Talpaz M, Hehlmann R, Quintas-Cardama A, Mercer J, Cortes J. Re-emergence of interferon-alpha in the treatment of chronic myeloid leukemia. Leukemia 2013; 27: 803-12.
7. Tarhini AA, Gogas H, Kirkwood JM. IFN-alpha in the treatment of melanoma. J Immunol 2012; 189: 3789-93.
8. Rosenblatt J, McDermott DF. Immunotherapy for renal cell carcinoma. Hematol Oncol Clin North Am 2011; 25: 793-812.
9. Santini SM, Lapenta C, Santodonato L, D'Agostino G, Belardelli F, Ferrantini M. IFN-alpha in the generation of dendritic cells for cancer immunotherapy. Handb Exp Pharmacol 2009; 188: 295-317.
10. Ferrantini M, Capone I, Belardelli F. Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie 2007; 89: 884-93.
11. Hatanaka K, Suzuki K, Miura Y et al. Interferon-alpha and antisense K-ras RNA combination gene therapy against pancreatic cancer. J Gene Med 2004; 6: 1139-48.
12. Ohashi M, Yoshida K, Kushida M et al. Adenovirus-mediated interferon alpha gene transfer induces regional direct cytotoxicity and possible systemic immunity against pancreatic cancer. Br J Cancer 2005; 93: 441-9.
13. Hara H, Kobayashi A, Yoshida K et al. Local interferon-alpha gene therapy elicits systemic immunity in a syngeneic pancreatic cancer model in hamster. Cancer Sci 2007; 98: 455-63.
14. Narumi K, Kondoh A, Udagawa T et al. Administration route-dependent induction of antitumor immunity by interferon-alpha gene transfer. Cancer Sci 2010; 101: 1686-94.
15. Udagawa T, Narumi K, Goto N et al. Syngeneic hematopoietic stem cell transplantation enhances the antitumor immunity of intratumoral type I interferon gene transfer for sarcoma. Hum Gene Ther 2012; 23: 173-86.
16. Hara H, Kobayashi A, Narumi K et al. Intratumoral interferon-alpha gene transfer enhances tumor immunity after allogeneic hematopoietic stem cell transplantation. Cancer Immunol Immunother 2009; 58: 1007-21.
17. Narumi K, Udagawa T, Kondoh A et al. In vivo delivery of interferon-alpha gene enhances tumor immunity and suppresses immunotolerance in reconstituted lymphopenic hosts. Gene Ther 2012; 19: 34-48.
18. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007; 25: 267-96.
19. Kobayashi N, Hiraoka N, Yamagami W et al. FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res 2007; 13: 902-11.
20. Byrne WL, Mills KH, Lederer JA, O'Sullivan GC. Targeting regulatory T cells in cancer. Cancer Res 2011; 71: 6915-20.
21. Nocentini G, Ronchetti S, Cuzzocrea S, Riccardi C. GITR/GITRL: more than an effector T cell co-stimulatory system. Eur J Immunol 2007; 37: 1165-9.
22. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002; 3: 135-42.
23. Nishikawa H, Kato T, Hirayama M et al. Regulatory T cell-resistant CD8+ T cells induced by glucocorticoid-induced tumor necrosis factor receptor signaling. Cancer Res 2008; 68: 5948-54.
24. Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 1991; 108: 193-9.
25. Ohtani H. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immun 2007; 7: 4.
26. Sato E, Olson SH, Ahn J et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005; 102: 18538-43.
27. Tan MC, Goedegebuure PS, Belt BA et al. Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J Immunol 2009; 182: 1746-55.
28. Cohen AD, Schaer DA, Liu C et al. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS ONE 2010; 5: e10436.
29. Mitsui J, Nishikawa H, Muraoka D et al. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Clin Cancer Res 2010; 16: 2781-91.
30. Yoshida K, Kondoh A, Narumi K, Yoshida T, Aoki K. Extracellular matrix interacts with interferon alpha protein: retention and display of cytotoxicity. Biochem Biophys Res Commun 2008; 376: 299-304.